key: cord-1051070-rwczf3h3
authors: Hallas, Donna; Spratling, Regena; Fletcher, Jason
title: Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines
date: 2021-05-31
journal: J Pediatr Health Care
DOI: 10.1016/j.pedhc.2021.04.001
sha: ea2e9bd587f29c2e545ee5f1bd1bbf3e4ec07b4c
doc_id: 1051070
cord_uid: rwczf3h3

Critical appraisal of randomized controlled trials (RCTs) determine rigor, quality, and whether the findings are applicable to the populations served in clinical practices. The authors conducted a rigorous analysis using the RCT Critical Appraisal Skills Programme (CASP) Checklist for the two RCTs Pfizer and Moderna conducted and the reporting of these RCTs using the CONSORT checklist. The goals for this analysis were twofold: 1). Enable healthcare providers to understand the methods and outcomes of these RCTs; 2). Enable healthcare providers and community leaders to become champions for the vaccines to reduce vaccine hesitancy among all populations. The analysis is presented using each of the eleven question on the CASP tool while comparing the methodology and results for each vaccine. The majority of CASP tool items were positive or ‘yes’ for both the Pfizer and Moderna RCTs. Items that were not scored as yes are discussed. The analysis outcomes revealed that both RCTs were rigorously conducted and provide an assurance to all healthcare providers and the public of the safety and efficacy of both vaccines to impact the astounding morbidity and mortality of COVID-19 disease. The authors believed that the analysis was an essential component of the distribution process to develop plans and communication strategies to reduce potential vaccine hesitancy and resistance.

vaccinations, randomized control trial, coronavirus, CASP critical appraisals checklist, reporting guidelines The 'warp speed' concept for the development, testing, clinical trials, and the Federal Drug Administration (FDA) emergency use authorization (EUA) of two coronavirus disease 2019 vaccines and the nationwide distribution of the vaccines -'shots in arms' -to combat the severe acute respiratory coronavirus 2 (SARS CoV-2) pandemic has brought to the forefront issues related to vaccine hesitancy. One way to address vaccine hesitancy is to critically analyze the methodology and results for the randomized clinical trials (RCTs) conducted for both FDA EUA COVID-19 vaccines: Pfizer (Polack et al., 2020) and Moderna (Baden, et al., 2021) and for providers to inform their patients of the outcomes of these RCTs.

Critical appraisal of RCTs determine rigor, quality, and whether the findings are applicable to the populations served in clinical practices. Specifically, the Critical Appraisal Skills Programme (CASP) Checklists (2018) includes an appraisal tool designed to evaluate RCTs. In addition, research journals require RCTs be reported using the Consolidated Standards of Reporting Trials (CONSORT, 2010) guidelines. Thus, we conducted a rigorous analysis using the RCT CASP tools for the two RCTs, Pfizer (Polack et al., 2020) and Moderna (Baden et al., 2021,) and the reporting of these RCTs using the CONSORT checklist. The authors present the findings from this analysis which revealed that both the Pfizer and Moderna vaccine demonstrated safety and efficacy. The goals for this analysis are twofold: 1) Enable healthcare providers to understand the methods and outcomes of these RCTs; and 2) Enable healthcare providers and community leaders to become champions for the vaccines to reduce vaccine hesitancy among all populations.

Both the Pfizer and Moderna vaccines are messenger ribonucleic acid (mRNA) vaccines. The mRNA-based vaccines have advantages in that they do not generate infectious components or have the potential to cause infection, do not affect the genes or genome of the person or host cell, do generate a strong immune response with only one or two low-doses of vaccine, and can be quickly produced in a large-scale to treat mass populations (Maruggi et al., 2019; Wang et al., 2020) . Once the gene sequence and antigen of the virus pathogen was determined, the mRNA vaccine can be rapidly produced. In addition, the success of mRNA vaccines for cancer and viral pathogens in creating antigen-specific immune responses have been studied and documented since the 1990s (Maruggi et al.) .

The BNT162b2 mRNA vaccine from Pfizer is a lipid nanoparticle-formulated vaccine that encodes a prefusion stabilized full-length spike protein of the virus that causes Covid-19, SARS-CoV-2 (Polack et al., 2020) . The mRNA-1273 vaccine from Moderna also encodes the full-length spike protein and is similar in composition to the Pfizer vaccine (Baden et al., 2020) . Once the vaccine is injected into the person or host, the mRNA protein is processed by immune cells that produce the targeted protein directly (Wang, Kream, & Stefano, 2020) . This replication of proteins subsequently activates B cells and T cells to recognize the newly produced viral protein and to make antibodies against SARS-CoV-2 (Wang et al.) .

In appraising the phase three RCTs of the vaccines, the CASP checklist for RCTs was used systematically for both the Pfizer and Moderna vaccine articles. The checklist for this critical appraisal tool comprises eleven questions designed with prompts to explore details of the study, focusing on validity of results, the details of the results, and whether the results are helpful (CASP, 2018) . We present our analysis using each question on the CASP tool while comparing the methodology and results for each vaccine.

Two terms, efficacy and effectiveness are used to assess healthcare interventions (Haynes, 1991) . Efficacy is defined as "the extent to which an intervention does more good than harm under ideal circumstances" (Haynes, p. 1) . Effectiveness is defined as a means of "assessing whether an intervention does more good than harm when provided under usual circumstances of healthcare practice" (Haynes, p. 1). Both RCTs report on the efficacy of the vaccines in preventing severe SARs CoV2 disease in individuals who were in RCTs to assess the efficacy of the vaccines. The effectiveness of the vaccines will be determined when data become available when a large number of individuals receive the vaccines in populations in the U.S. and throughout the world. Pfizer and Moderna used different statistical methodologies to determine vaccine efficacy.

Pfizer: Vaccine efficacy (VE) describes the impact of the vaccine on the primary endpoint of infection. VE is often misinterpreted as the percentage of vaccinated individuals who will not become infected when exposed to the virus. What VE does reflect is probability of infection in the treatment group as compared to the placebo group. Specifically it is calculated as 1 -(p treatment /p control ), where p treatment = the probability or rate of infection in the treatment group, and p control = the probability of infection in the control group. VE can range from 0% (vaccine offers no protection from infection) to 100% (complete protection). In the study sample, it was found that the rate of infection in the vaccination group was 4.9% that of the placebo group, and so VE is determined to be 95%.

Since these results are based on sample data (and not the entire population), we need to determine the likelihood of this result of the VE in the larger population. This is done by using the null hypothesis that VE is <30% (pre-specified criterion). The Bayesian beta-binomial model was used to calculate the likelihood that the true VE in the population exceeds this threshold (>30%) based on the effect observed in the sample (Yang, Gilbert, Longini, & Halloran, 2008) . This is the 99.9% probability that is reported. That is, given the findings in the sample (VE = 95%), there is a 99.9% likelihood that the true effect of the vaccine (VE) in the population exceeds 30%.The Bayesian methods for calculating the probability of VE are standard methods and provide assurance of VE.

Moderna used different statistical methods to assess VE, using a stratified Cox proportional hazards model to determine the percentage of hazard reduction associated with the vaccine relative to the placebo. However, the statistical methods achieved comparable outcomes for analysis of VE at 94.1% as the Pfizer RCT. VE was assessed for all participants who received at least one dose of the Moderna vaccine based on a modified intention-to-treat based on the population who received the vaccine without evidence of COVID-19 disease on day 1 before the first vaccine was administered and participants who received two doses of the vaccine without a deviation from the protocol (Baden, et al, 2020) . This statistical methodology also provides assurance of VE.

Pfizer: Yes, the Pfizer RCT focused on the "safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 ug of BNT162b2 in preventing COVID-19 in persons 16-years of age and older" (Polack, et al., 2020, p. 2) . Individuals admitted to the clinical trial were healthy or had stable chronic medical conditions. Individuals excluded from the study were those who had a medical history of having COVID-19 disease, treatment with immunosuppressive therapy, or diagnosis with an immunocompromising condition. The primary end points for Pfizer RCT were data solicited from an electronic diary from study participants concerning local or systemic adverse events and use of antipyretics within 7-days of receiving the vaccine. The major secondary end points for the Pfizer vaccine was the efficacy of the vaccine to protect against severe COVID-19 disease. The intervention Pfizer vaccine BNT162b2, an mRNA vaccine, was administered in a two-dose regimen of 30 ug per dose, with 0.3 mL per dose, administered in the deltoid, 21 days apart. The placebo control group received 0.3 mL of saline per dose, also administered in the deltoid, 21-days apart. All study participants were observed for 30 minutes after receiving each dose.

Moderna: Yes, the Moderna RCT addressed a critical and timely issue of SARS-CoV-2 infection, a worldwide pandemic with devastating mortality and morbidity, and extremely high level of contagiousness. This RCT studied the population of adults stratified based on age and Covid-9 complications risk criteria with groups of persons 65 years of age or older, persons younger than 65 years of age who were at risk for severe Covid-19, and persons younger than 65 years of age without risk. Participants were categorized as being at risk for severe Covid-19 if they had at least one of the following based on the Centers for Disease Control and Prevention (CDC) criteria at the time of trial design: chronic lung disease, cardiac disease, severe obesity, diabetes, liver disease, or human immunodeficiency virus (HIV) infection. The intervention was the mRNA-1273 vaccine or the saline placebo control. The vaccine was provided as a sterile liquid at a concentration of 0.2 mg per milliliter in a volume of 0.5 ml containing 100 μg of mRNA-1273 and the placebo control was 0.5 ml of saline. Either were administered by intramuscular injection into the deltoid muscle in a two-dose regimen given 28 days apart in the same arm. Safety outcomes included adverse events, and cases of Covid-19 and severe Covid-19. Moderna specified efficacy outcomes as primary and secondary endpoints with the primary endpoint being efficacy of the vaccine in preventing a symptomatic infection at least 14 days after the second injection of vaccine. The secondary endpoints were efficacy in preventing an infection with severe symptoms, efficacy of a single dose, having any symptoms of infection, and having a positive test.

Thus, efficacy included not only preventing infection, but also preventing symptomatic or severe infections.

Pfizer: Yes, all study participants, who were screened to meet study eligibility criteria, completed information in an interactive Web-based system used to randomly assign study participants, 16-years old and older, in a 1:1 ratio, to the placebo controlled or vaccine (BNT162b) intervention groups.

Moderna: Yes, the participants were randomized in a one-to-one ratio to receive vaccine or placebo control, using a centralized interactive response technology system that was blinded to study staff and those receiving the vaccine.

Question three: Were all of the patients who entered the trial properly accounted for at its conclusion?

Pfizer: No, all study participants in the vaccine intervention group or the placebo control group were accounted for in a detailed flow diagram and in the narrative that detailed the characteristics of study participants. However, unique to the Pfizer RCT, was that the study was multinational, with 152 participating sites worldwide. The demographic characteristics of the participant States. Therefore, it is not clear if participants from South Africa were accounted for in the study. In addition, 196 patients with a diagnosis of HIV positive participated in the study but their data was to be analyzed separately and was not included in this article.

Yes, all participants who were either intervention with vaccine or control with placebo control are detailed in a flow diagram as directed by the CONSORT guidelines and also detailed in the narrative of the article. The participants were analyzed in the groups on which they were analyzed and in subgroups of age, age and health risk, sex, race and ethnicity, and risk for severe Covid-19 illness.

The RCT was not stopped early.

Question four: Were patients, health workers, and study personnel blind to treatment/intervention? Pfizer: Yes, patients, health workers, and study personnel were blinded to study participant placebo control and vaccine intervention group assignments. In addition, site staff who were responsible for safety evaluations by observing participants for 30-minutes post vaccination, did not have any knowledge about group assignments.

No, study staff and those receiving the vaccine were blind to treatment/intervention and placebo control; however, vaccine doses were prepared and administered by pharmacists and vaccine administrators who were aware of treatment/intervention and placebo control assignments.

These pharmacists and vaccine administrators had no other role in the RCT.

Question five: Were the groups similar at the start of the trial? Pfizer: Yes, the demographic characteristics, of sex, race or ethnic groups, country, age entering the study, age at vaccination, and body mass index, and coexisting conditions were similar for the vaccine intervention and placebo controlled groups at the start of the trial.

Moderna: Yes, the groups of analysis in the intervention and control of the RCT were similar. In addition, the selection of study sites and enrollment were adjusted to increase the number of persons from racial and ethnic groups in the RCT, resulting in a population described as generally representative of demographics in the United States.

Question six: Aside from the experimental intervention, were the groups treated equally?

Pfizer: There are two answers for this question. Yes, on the days of their injection, all participants were monitored for 30 minutes after receiving the injection. Participants in both the vaccine intervention and the placebo controlled groups were prompted by an electronic diary to record specific local or systemic adverse events and use of antipyretics or pain medication within 7-days after receipt of each dose per their assigned groups. All participants could also record in the electronic diary without prompting any adverse event through 1-month after the second dose and unsolicited serious adverse events through 6-months after the second dose. Also cannot tell, as no information was provided regarding instructions to participants, e.g., were all participants instructed to wear masks, keep social distance, and to wash hands frequently? What was the protocol for testing all participants for COVID-19 infection before and after receiving the vaccine? For those who were positive after receiving the vaccine, was contact tracing completed?

Moderna: Yes, participants were monitored for solicited local and systemic adverse events (7 days after each injection), unsolicited adverse reactions (28 days after each injection), adverse events leading to discontinuation from a dose and/or RCT, serious adverse events (day 1 through 759 days, and cases of Covid-19 and severe Covid-19 continuously from randomization onward), regardless of intervention or placebo control. As previously noted, injections of 0.5 ml were given 28 days apart in the same arm.

Pfizer: Based on the evidence from the RCT, the Pfizer vaccine was 52% effective in the interval between the first and second dose and 91% effective in the first 7 days after dose 2. Full efficacy of 95% protection against COVID-19 in persons 16-years of age and older after dose 2 for those in the vaccine intervention group (Credible interval [CI] 90.3 to 97.6). 

Pfizer: The researchers reported 8 cases of COVID-19 with onset at least 7-days after the second dose among the vaccine intervention group (BNT162b2b) and 162 cases among those randomly assigned to the placebo controlled group. Ten cases of severe COVID-19 were reported after the first dose was administered to both the vaccine intervention and the placebo controlled group: 1 case occurred in the intervention group and 9 cases in the placebo control group.

Moderna: In addition to the effects of the intervention noted above, participants assessed 14 days after the first dose of vaccine for the presence of SARS-CoV-2 infection, noting 225 cases with placebo control and 11 cases with vaccine, indicating a VE of 95.2% [95% CI, 91.2 to 97.4]. Participants who were SARS-CoV-2 seropositive at baseline were also included per-protocol in the analysis (187 cases with placebo control, 12 cases with cases; one participant assigned to receive vaccine was inadvertently given placebo control, indicating a VE of 93.6% [95% CI, 88.6 to 96.5]. These data conclude a precise treatment effect among varying analyses of the RCT.

Pfizer: Yes, study participants were similar to those who would receive the vaccine in the U.S., and to those study sites in Argentina and Brazil as efficacy data is reported for those countries.

Moderna: Yes, the participants in the trial were similar enough to those who would be administered the vaccine and the results can be applied to a variety of populations, based on age, healthy or with a health risk or chronic condition, race and ethnicity, and sex. Question ten: Were all clinically important outcomes considered? Pfizer: No, it was not possible to consider all clinically important outcomes given the 'warp speed' conduction of the RCT which was essential as the world is living in a pandemic. The researchers are planning to continue follow-up of study participants for the next two years. At this time, there is a severe shortage of available vaccines and there is consideration of administering the single dose which showed a 52% efficacy rate seven days after the initial dose.

No, all clinically important outcomes were not considered as this RCT was of short duration due to the current Covid-19 pandemic. Other outcomes to consider are efficacy of single dose of vaccine, reduced or half doses of vaccine, extended interval between two-dose regimen (e.g. greater than 28 days between doses), and long-term-efficacy of the vaccine and whether booster doses will be needed in the future. However, these outcomes do not affect the decision to proceed with use of the vaccine to prevent morbidity and mortality in the population at this time, focusing on risk for severe Covid-19 such as age and health risk. 

As part of the appraisal process, the RCTs for both the Pfizer and Moderna article were evaluated using the CONSORT 2010 checklist of information to include when reporting a RCT. Both RCTs failed to include identification as a RCT in the title. Both articles were evaluated as including all other key information for reporting a RCT; however, we felt that it was important to note that both included supplementary materials at the journal website.

We conducted a rigorous analysis of the two RCTs using the CASP checklist (2018) and we found that both the Pfizer and Moderna vaccine demonstrated safety and efficacy. The majority of checklist items were positive or 'yes' for both the Pfizer and Moderna RCTs. For the Pfizer vaccine, all of the patients who entered the trial were not properly accounted for at its conclusion (Question three). For the Moderna vaccine, study personnel of pharmacists and vaccine administrators were not blind to treatment/intervention (Question four). All clinically important outcomes were not considered for both vaccines (Question ten); however, this was attributed to the need for a vaccine in a pandemic with significant morbidity and mortality. In addition, we conducted an analysis of the reporting of these RCTs using the CONSORT checklist (2010) and found that both the Pfizer and Moderna vaccine RCT articles included the necessary details for reporting a RCT with the exception of not including RCT in the title.

In using the CASP checklist, we noted that the checklist does not account for vaccine-specific RCT concerns such as side effects of the vaccine. We found the side effects for both vaccines to be mostly minor, and local or specific to vaccine administration sites. In a critical appraisal of a vaccine or other types of RCT, it may be helpful to focus questions specific to the RCT.

Of note, is the dosing for Moderna at 100 ug per dose of mRNA-123 as compared to Pfizer's dosing of 30 ug. Thus, the Moderna vaccine is providing three times the amount per dose as Pfizer with no difference in outcomes. As more is learned about these vaccines as the initial clinical trials are further studied, long term safety and efficacy both in the laboratory and from continued analysis of outcomes for individuals who participated in the clinical trials, dosage recommendations will be further analyzed.

Data continues to be collected and analyzed for the phase 2/3 clinical trial phase to determine vaccine immunogenicity and durability of the immune response. In addition, all individuals who have taken the vaccine in the United States (U.S.) should complete the CDC (www.cdc.gov) post vaccination monitoring system, Vaccine Adverse Event Reporting System (VAERS), to assure a continued knowledge base for COVID-19 and vaccine safety, efficacy and immunogenicity responses.

Nurse practitioner educational programs introduce CASP tools in the research and evidencebased practice courses and have students continue to use the tools throughout clinical courses to enable students to conduct a critical analysis of published research studies with the goal of determining whether the study outcomes can be applied to their patient populations. All practicing clinicians should continue this analysis as new studies emerge and new treatment modalities become available for implementation into clinical practice. Thus, the authors conducted the analysis of the RCTs published by both Pfizer and Moderna after receiving emergency use authorization for distribution and administration of vaccines by the Food and Drug Administration (FDA). The authors believed that the analysis was an essential component of the distribution process to develop plans and communication strategies to reduce potential vaccine hesitancy and resistance. The analysis outcomes revealed that both RCTs were rigorously conducted and provide an assurance to all healthcare providers and the public of the safety and efficacy of both vaccines to impact the astounding morbidity and mortality of COVID-19 disease. When asked by patients, "Do you recommend the Pfizer and Moderna vaccines?" NPs should review their patients' health status, and if the patient meets the study populations, can confidently say, yes, take the vaccine when available to you.

Pfizer and Moderna are currently conducting RCT for these vaccines in children, and we can assure parents that when the clinical trials are completed and the evidence is published, that NPs will review the outcomes and make recommendations for practice at that time. In addition, NPs and all healthcare providers are awaiting the results of the longer term immunogenicity studies for both of these vaccines to make additional recommendations for their patient populations as to whether a booster dose will be needed in the coming years.

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

CONSORT statement

CASP Randomised Controlled Trial Checklist

Comparison of the quality of pediatric randomized controlled trials published in both nursing and Medical Journals: Adherence to the CONSORT Statement

Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving

mRNA as a transformative technology for vaccine development to control infectious diseases

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

An evidence based perspective on mRNA-SARS-CoV-2 vaccine development

A Bayesian framework for estimating vaccine efficacy per infectious contact